Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.

Antimicrobial agents and chemotherapy - 1 Jun 2004

Lu Liangjun, Pilot-Matias Tami J, Stewart Kent D, Randolph John T, Pithawalla Ron, He Wenping, Huang Peggy P, Klein Larry L, Mo Hongmei, Molla Akhteruzzaman

Abstract excerpt

BILN 2061 is a novel, specific hepatitis C virus (HCV) NS3 serine protease inhibitor discovered by Boehringer Ingelheim that has shown potent activity against HCV replicons in tissue culture and is currently under clinical investigation for the treatment of HCV infection. The poor fidelity of the HCV RNA-dependent RNA polymerase will likely lead to the development of drug-resistant viruses in treated patients....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Macrocyclic Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Conformation

Share to Quinolines

Share to Replicon

Share to Serine Proteinase Inhibitors

Share to Thiazoles

Share to Viral Plaque Assay

Source

Open in PubMed Open full text

Identifiers

PMID: 15155230
DOI: 10.1128/AAC.48.6.2260-2266.2004
PMCID: PMC415624

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.PMID 15155230Read ↗

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.Semantic proximity Read ↗

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.Semantic proximity Read ↗

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.Semantic proximity Read ↗

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.Semantic proximity Read ↗

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.Semantic proximity Read ↗

Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.Semantic proximity Read ↗

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.Semantic proximity Read ↗

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.Semantic proximity Read ↗

Hepatitis C virus resistance to protease inhibitors.Semantic proximity Read ↗

In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.Semantic proximity Read ↗

In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.Semantic proximity Read ↗

Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.